Kenneth Beagley, PhD

Queensland Univ of Technology
Inst. of Health & Biomedical Innovation
Kelvin Grove Campus
Brisbane QLD Australia 4059

Biographical Sketch: Ken Beagley is a Professor of Immunology and Deputy Director at the Institute of Health and Biomedical Innovation at Queensland University of Technology. He has worked in the area of mucosal immunology for the past 25 years at the University of Alabama at Birmingham and the University of Newcastle prior to moving to QUT. Current research interests focus on immunity to sexually transmitted infections, in particular Chlamydia trachomatis. The aim of these studies is to define and differentiate the immune parameters of immune-mediated inflammatory pathology caused by Chlamydia infection from the immune mechanisms that can protect against chlamydial infection and to use this information to develop effective chlamydial vaccines. This work involves the use of both mouse and guinea pig models of chlamydial infection and has recently been extended to include development of a chlamydial vaccine for the koala. In all of these studies novel needle-free vaccination routes such as intranasal, sublingual and transcutaneous immunization, which target immunity to the female and male reproductive tracts are being evaluated alongside conventional injectable methods of immunization. Other research interests include the effects of chlamydial infections on spermatogenesis and ovarian function, the development of novel topical microbicide/spermicide dual action therapeutics and modulation of innate and adaptive immunity by sex hormones.

Any personal financial relationships? No

I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.

I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.

I agree to provide educational content and resources in advance for review if requested by ICMI.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 06/30/2015 by Kenneth W Beagley

Papers:
Opening Keynote Lecture
Presidential Session
ICMI Awards, Keynote Lectures
Inflammation or Protection: The Role of IL-17 in Chlamydial Infection
F.69 Male IgG Seroconversion to Urogenital Chlamydial Infection Exacerbates Immunopathology in Females
F.119 Oral immunization induces an effective mucosal immune response that protects mice against intravaginal HSV-2 challenge

	I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.
	I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.
	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.
	I agree to provide educational content and resources in advance for review if requested by ICMI.
	If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
	If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".